Freenome, Inc. (FRNM) News
Follow Freenome, Inc. (FRNM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
FRNM initiated Buy at Guggenheim with $21.00 target
Guggenheim initiates coverage of FRNM with a Buy rating and a $21.00 price target.
EQUITY | Aug 20, 2026, 11:56 AM UTC
M
BTIG and Jefferies initiate FRNM at Buy with $17 target
BTIG and Jefferies initiate coverage of FRNM with Buy ratings and a $17 price target.
EQUITY | Aug 17, 2026, 10:21 AM UTC
M
FRNM initiated with Outperform at Leerink; PT $18
FRNM is initiated with an Outperform rating at Leerink and assigned a $18 price target, according to TradeXchange Newsdesk.
EQUITY | Aug 14, 2026, 10:27 AM UTC
H
FRNM Gets FDA Breakthrough Device Designation
FRNM's blood-based lung cancer screening test gets FDA breakthrough designation
EQUITY | Aug 12, 2026, 01:00 PM UTC
L
Freenome, Abbott announce FDA approval of SimpleScreen CRC
Freenome (FRNM) and...
EQUITY | Jul 27, 2026, 12:12 PM UTC